Medical Technology Company Closes $10 Million Financing

RenovoRx, Inc., a medical technology company developing a catheter-based approach to treating pancreatic cancer, closed a $10 million financing round led by Boston Scientific, btov Partners, and existing investors Astia Angels, the Angels’ Forum, the Halo Fund III, L.P., Golden Seeds, and Acorn Campus Taiwan.

The company’s RenovoCath™ System is a drug-device combination designed to deliver chemotherapy directly to solid tumors. The company says that based upon early studies of people with locally advanced pancreatic cancer and the potential to address a significant unmet need, the FDA recently granted RenovoCath an Orphan Drug Designation, and approved an Investigational New Drug application for it to advance directly to a Phase III clinical study.